|Mr. Theodore R. Schroeder||CEO & Director||707.62k||N/A||1955|
|Dr. Steven P. Gelone||Pres & COO||667.5k||N/A||1968|
|Dr. Colin Broom||Director||39.13k||N/A||1956|
|Dr. Jennifer Schranz M.D.||Chief Medical Officer||620.85k||N/A||1965|
|Mr. Gary L. Sender||Chief Financial Officer||N/A||N/A||1962|
|Mr. Robert L. Crotty||Gen. Counsel & Sec.||N/A||N/A||1974|
|Mr. Francesco Maria Lavino||Chief Commercial Officer||N/A||N/A||1973|
|Mr. Werner Heilmayer||VP of CMC & IP||N/A||N/A||N/A|
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; for the treatment of acute bacterial skin and skin structure infection; and that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, osteomyelitis, and prosthetic joint infections. It is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Nabriva Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.